Jake Simson is a Partner at RA Capital Management. He previously served on the board of directors of Audentes Therapeutics, Inc., a publicly traded AAV-based genetic medicines company, from July 2013 to July 2017 and CRISPR Therapeutics AG, a publicly traded biopharmaceutical company, from April 2014 to June 2019. → Protein degradation outfit C4 Therapeutics has made room for Atara Biotherapeutics CFO Utpal Koppikar on the board of directors. Learn More about insider trades at C4 Therapeutics. 7 brokers have issued 1 year price objectives for C4 Therapeutics' stock. Their forecasts range from $20.00 to $63.00. On average, they anticipate C4 Therapeutics' share price to reach $48.50 in the next twelve months. This suggests a possible upside of 76.1% from the stock's current price. C4 Therapeutics disclosed the collaboration with Roche today—as well as its formal launch with the closing of a $73 million Series A financing whose investors included Roche and … Our core multi-peptide vaccine was developed in the labs of world-renowned oncology researchers at the Dana-Farber Cancer Institute. Prior to joining C4 Therapeutics, Andy was Senior Director, Center for Development of Therapeutics at The Broad Institute of MIT and Harvard. Dr. Farid currently serves on the board of directors of ShouTi. Andrew currently serves as President, Chief Executive Officer and a member of the Board of Directors of C4 Therapeutics (C4T). Marc Cohen is a co-founder and Executive Chairman of NextRNA Therapeutics. Director Of C4 Therapeutics Sold $3.98 Million In Stock. Serves on the Supervisory Board of Qiagen and on the Scientific Advisory Board of C4 Therapeutics, Isoplexis, Mana Therapeutics and was on the Scientific Advisory Board of Loxo Oncology. Dr. Kauffman co-founded Karyopharm Therapeutics, Inc. in 2008 and served as its Chief Executive Officer from January 2011 through May 2021 and as a … Appleby Mauritius advised on the matter. He is also Chairman of the Board of Directors of Biogen, Inc., Exelixis, Inc., and Regulus Therapeutics, Inc. 16 March 2022 C4 Therapeutics Appoints Utpal Koppikar to Board of Directors. John Rice, PhD Executive Chairman. C4 Therapeutics Appoints Glenn Dubin to Board of Directors. : Other: Scientific Founder of … C4 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39567 47-5617627 (State or other jurisdiction. He currently serves on the board of directors at Editas Medicine. C4 Therapeutics, Inc. (CCCC) Moves to Buy: Rationale Behind the Upgrade ... C4 Therapeutics Appoints Utpal Koppikar to Board of Directors 03/16/22-4:05PM EST GlobeNewswire 333–248719) filed on … He serves as editor-in-chief of Clinical Cancer Research. Founder and Co-CEO of Cobro Ventures; Co-founder or investor of >10 companies, including C4 Therapeutics, Frequency, Regency, Acetylon; Expertise: VC investment and company building C4 Therapeutics Appoints Utpal Koppikar to Board of Directors: Mar 10: 87 Biggest Movers From Yesterday: Mar 9: C4 Therapeutics CFT8634 gets FDA orphan drug status for soft tissue sarcoma: Mar 9: C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma: Mar 8 GALWAY, Ireland and SAN DIEGO, March 23, 2022 /PRNewswire/ -- ONK Therapeutics, an innovative company dedicated to developing optimally engineered natural killer (NK) cell therapies to cure patients with cancer, today announced that it has appointed Allan Reine as independent Non-Executive Director to its Board. Marc Cohen. WATERTOWN: C4 Therapeutics (C4T), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, announced the hiring of Andrew Hirsch as the Company’s incoming chief executive officer. He is also Chair of the Board of Directors of Hemab Therapeutics and a member of the Board of Directors of Agios Pharmaceuticals, Beam Therapeutics and the Biotechnology Industry Organization, where he was Chair from 2017-2019. CCCC Stock Overview. Jason Fisherman has 2 current jobs as Member, Board Of Directors at AlloMek Therapeutics and President & CEO at C4 Therapeutics. Workshops are conducted throughout the year and focus on key functional areas within ITMAT. C4 Therapeutics disclosed the collaboration with Roche today—as well as its formal launch with the closing of a $73 million Series A financing whose investors included Roche and … Prior to joining Yonjin Venture, he was a global lead of business development and external innovation for neuroscience at Sanofi Genzyme. Transforming medicine with novel early stage therapies that eliminate disease-causing proteins #proteindegradation | C4 Therapeutics (C4T) is a … Insiders at C4 Therapeutics own 21.0 % of the company. C4 Therapeutics (NASDAQ:CCCC) pulls back 8.2% this week, but still delivers shareholders notable 85% return over 1 year. Additionally, Jason Fisherman has had 3 past jobs including Managing Director at Advent International. – Appointment Reflects C4T's Continued Commitment to Corporate Governance to … Simply Wall St. Sep-17-21 10:27AM. View detailed CCCC description & address. WATERTOWN, Mass., March 16, 2022 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Utpal Koppikar, MBA, to … – USA, MA – C4 Therapeutics, Inc., today announced the addition of Glenn Dubin to the Company’s Board of Directors. ; Oncopeptide AB: Consultancy. Utpal Koppikar C4 Therapeutics Appoints Utpal Koppikar to Board of Directors – Utpal Koppikar, Veteran Life Sciences Industry Financial Executive, Appointed as … William T. McKee Chief Financial Officer & Treasurer, C4 Therapeutics, Inc. Mr. William T. McKee, CPA, is a Chief Financial Officer & Treasurer at C4 Therapeutics, Inc., an … In 2009, Kenneth Anderson, M.D., Joouen Bae, Ph.D., and Nikhil Munshi, M.D. Glenn Dubin joins Board of Directors of C4 Therapeutics. Find the latest Insider Activity data for C4 Therapeutics, Inc. Common Stock ... Board of Directors; Careers; Press Center ... directors and any beneficial owners of more than 10% of a … Our Company. Dr. This targeted protein degradation approach offers advantages over traditional therapies, including the … He is also a founder and Chairman of the Board of Microbial Machines and Courage Therapeutics and serves as a Director for NextRNA. – Utpal Koppikar, Veteran Life Sciences Industry Financial Executive, Appointed as Independent Member of the Board of Directors, Chair of Audit Committee and He is currently a member of the Board of Directors of Kymera (KYMR) and Generation Bio (GBIO), and is Chair of the Board of Directors of Disc Medicine, Jnana and NodThera. Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. Dr. Reine brings significant experience to … Dr. Stelios Papadopoulos is a co-founder and Chairman/Treasurer of Fondation Santé. He previously founded MolecularMD, which was acquired by ICON. Find the latest historical data for C4 Therapeutics, Inc. Common Stock (CCCC) at Nasdaq.com. Board of Directors Success is accelerated by experience, collaboration and leadership. : Anderson: Sanofi-Aventis: Membership on an entity's Board of Directors or advisory committees; Oncopep and C4 Therapeutics. C4 Therapeutics Appoints Utpal Koppikar to Board of Directors - March 16th, 2022 Seer Announces Appointment of Scott D. Thomas as Chief Commercial Officer - March 16th, 2022 Synthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results - March 16th, 2022 C4 Therapeutics, Inc. provides new class of targeted protein degradation. Brian currently serves on the board of directors at Amgen and Vincerx Pharma. Read more Fifth Amended and Restated Certificate of Incorporation of C4 Therapeutics, Inc. 3.2 : Second Amended and Restated Bylaws of C4 Therapeutics, Inc. (incorporated by reference to Exhibit 3.5 to the Registration Statement on Form S-1 (File No. C4 Therapeutics welcomes Utpal Koppikar to its Board of Directors as Chair of the Audit Committee. Mr. Needham is currently the Director and Head of the Biopharmaceutical practice at Broadview Ventures. The Company is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. Company profile for C4 Therapeutics Inc. including key executives, insider trading, ownership, revenue and average growth rates. [TODAY IS YOUR LUCKY DAY] Get 50% OFF and get 2 bear market beating options trade straight to your inbox and SMS every month! He co-founded Compass in 2014 following conceptual discussions while he was a venture partner at OrbiMed. (See Shoals stock forecast on TipRanks) C4 Therapeutics (CCCC) Let's move on now to the biotech sector. March 17, 2022. Co-founder and Chairman of Acetylon Pharmaceuticals, Inc. and ONCOPEP, Inc. C4 THERAPEUTICS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Shares of C4 Therapeutics closed at $23.51 yesterday. C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. C4 Therapeutics, Inc. is a biopharmaceutical company. WATERTOWN, Mass.-- ( BUSINESS WIRE )-- C4 Therapeutics (C4T), today announced the addition of Glenn Dubin to the Company’s Board of Directors. Dr. Flaherty joined the NCI Board of Scientific Advisors in 2018 and AACR Board of Directors in 2019. [TODAY IS YOUR LUCKY DAY] Get 50% OFF and get 2 bear market beating options trade straight to your inbox and SMS every month! These workshops have been coordinated by the leaders of our research programs and cores and address the practicalities of technologies and approaches of relevance to Translational Medicine and Therapeutics. Andy Phillips is a Managing Director at Cormorant Asset Management, LP. Mr. Hirsch comes to C4T from Agios Pharmaceuticals where he was chief financial officer … Anderson:Sanofi-Aventis: Membership on an entity's Board of Directors or advisory committees; Oncopep and C4 Therapeutics. They sold a total of 202,076 shares worth more than $9,324,871.82. C4 Therapeutics Appoints Utpal Koppikar to Board of Directors March 16, 2022 | benzinga.com Brokerages Expect C4 Therapeutics, Inc. (NASDAQ:CCCC) Will Post Earnings of … 5 Stars. C4 Therapeutics Inc. C4 Therapeutics, Inc. provides new class of targeted protein degradation. Previously, he served on the board of Nimbus Therapeutics, a biotechnology company he helped found in 2009. C4 Therapeutics (C4T) is a clinical-stage biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. March 16, 2022. – Utpal Koppikar, Veteran Life Sciences Industry Financial Executive, Appointed as Independent Member of the Board of Directors, Chair of Audit Committee and Member of Organization, Leadership and Compensation Committee –. Andrew joined the Editas Medicine Board of Directors in May 2017 with more than 25 years of experience in a range of strategic and operating business roles, including more than 20 years in the biotech industry. Co-founder and Chief Executive Officer, Compass Therapeutics. The mailing address of our principal executive offices is C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, … More than 20 million cats eat and enjoy Friskies products each day. This is an example of the _____ motive for saving. He serves as editor-in-chief of Clinical Cancer Research. – Utpal Koppikar, Veteran Life Sciences Industry Financial Executive, Appointed as Independent Member of the Board of Directors, Chair of Audit Committee and Member of Organization, Leadership... | March 16, 2022 Glenn Dubin has served as a member of the Board of Directors since March 2021. The Board of Directors of C4 Therapeutics, Inc. is using this proxy statement to solicit proxies for use at the Annual Meeting. He brings three decades of experience leading global, multi-strategy organizations across a wide range of industries to C4T’s Board. Dr. Bradner is a scientific cofounder of C4, along with Ken Anderson, M.D., and Nathanael Gray, Ph.D., both of Dana-Farber. However, Dr. Bradner will no longer have involvement with C4, the company said, due to his position at NIBR. C4 Therapeutics (NASDAQ:CCCC) pulls back 8.2% this week, but still delivers shareholders notable 85% return over 1 year. He is a co-founder of C4 Therapeutics and has served as a member of the Board of Directors and as Executive Chairman since October 2015. Board of Directors. REDWOOD CITY, Calif. and WUHAN, China, Feb 25, 2021 (GLOBE NEWSWIRE) – XWPharma Ltd. today announced that Glen Giovannetti has been appointed to the company’s Board of Directors. Mr. Dubin is the Principal of Dubin & Co. LP, a private investment company based in New York. Chauhan:Oncopeptide AB: Consultancy; consultant to Stemline Therapeutics, Inc., and Equity owner in C4 Therapeutics. Profile Summary. Thomas J. Schuetz, MD, PhD has over 20 years of experience in oncology, biopharmaceutical drug development and life science venture investing. – USA, MA – C4 Therapeutics, Inc. (Nasdaq: CCCC), a clinical-stage biopharmaceutical company today announced the appointment of Utpal Koppikar to its board of directors.…. Related Post. Password requirements: 6 to 30 characters long; ASCII characters only (characters found on a standard US keyboard); must contain at least 4 different symbols; Mr. Dubin is the Principal of Dubin & Co. LP, a private investment company based in New York. C4 THERAPEUTICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. Previously, he was a Professor of Chemistry atRead More 652.MYELOMA: PATHOPHYSIOLOGY AND PRE-CLINICAL STUDIES, EXCLUDING THERAPY | NOVEMBER 5, 2020 Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application Annamaria Gulla, MD,1 Eugenio Morelli, MD,2,3 Mehmet Kemal Samur, … ; Oncopeptide AB: Consultancy. Director Of C4 Therapeutics Sold $3.98 Million In Stock. Forward-Looking Statements. He also has serves on the scientific advisory boards of Aptose Biosciences and Grail. Michael Kauffman, M.D., Ph.D., has served as a member of our Board of Directors since December 2016. Denali’s Board of Directors combines expertise across industry, academia, drug development and the investment community, unified by the mission to improve the lives of patients. VANCOUVER, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Absci Corporation ABSI, the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the appointment of Andreas Busch, PhD, to its Board of Directors. Koppikar also held senior finance roles at Amgen and Gilead. Main is a highly experienced biopharmaceutical executive … Before joining Cormorant, he was the President and Chief Executive Officer of C4 Therapeutics. Glenn is the Principal of Dubin & Co., a private investment company based in New York. Since 2012, Glenn has been a member of the Board of Directors and lead shareholder of Castleton Commodities International LLC, a global merchant energy company active in the physical and financial … BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)--Mar 23, 2022--Orum Therapeutics, a biotechnology company pioneering the development of tumor-directed targeted protein degraders to treat cancer, today announced the appointment of David Main to the Company’s Board of Directors.Mr. Consultancy, Other: Equity owner in C4 Therapeutics. Mr. Shanahan has served on the Boards of Directors of Molson, Mead, Inc. and Duracell (then owned by KKR), Diageo PLC, MSD Performance Group, a privately held company, Life Technologies, Inc. and Visa, Inc. Fred has founded numerous biotech companies with successful exits, including Pear Tree Pharmaceuticals, Javelin Pharmaceuticals and PolaRx Biopharmaceuticals. Executive Chairman of C4 Therapeutics. In 2013 he co-founded Loxo Oncology, served on the Board of Directors and chaired the Scientific Advisory board until its acquisition by Eli Lilly for $8 billion. AlloMek Therapeutics Member, Board Of Directors Jun 2018. C4 Therapeutics is a biopharmaceutical company operating in the targeted protein degrader space. WATERTOWN, Mass, September 8, 2020 – C4 Therapeutics, Inc. (C4T), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, today announced the hiring of Andrew Hirsch as the Company’s incoming chief executive officer.Mr. MINNEAPOLIS, Nov. 6, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a family of brands with a unique and leading portfolio of reagents and instruments for life science and clinical research, today announced the signing of an agreement with C4 Therapeutics, Inc. to acquire an exclusive license for the Achilles-TAG (aTAG) degradation platform. BOSTON & DAEJEON, South Korea-- (BUSINESS WIRE)--Mar 23, 2022-- Orum Therapeutics, a biotechnology company pioneering the development of tumor-directed targeted protein degraders to treat cancer, today announced the appointment of David Main to the Company’s Board of Directors. Co-founder and Chief Executive Officer Bublup, Inc. and COBRO Ventures, Inc. He is a co-founder of C4 Therapeutics and has served as a member of the Board of Directors and as Executive Chairman since October 2015. Appointment Reflects C4T’s Continued Commitment to Corporate Governance to Support Company Growth He is also a founder and Chairman of the Board of Microbial Machines and Courage Therapeutics and serves as a Director for NextRNA. Trustee of the Dana-Farber Cancer Institute. Fred has founded numerous biotech companies with successful exits, including Pear Tree Pharmaceuticals, Javelin Pharmaceuticals and PolaRx Biopharmaceuticals. Sign up for your weekly dose of feel-good entertainment and movie content! He serves as a Management Advisor to ValueAct Capital, a San Francisco-based hedge fund. Member, Board of Directors. Dr. Flaherty joined the NCI Board of Scientific Advisors in 2018 and AACR Board of Directors in 2019. About C4 Therapeutics C4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural C4 Therapeutics Appoints Utpal Koppikar to Board of Directors benzinga.com - March 16 at 4:27 PM Brokerages Expect C4 Therapeutics, Inc. (NASDAQ:CCCC) Will Post Earnings of -$0.62 Per Share CCCC Stock Overview. Jake works on both public and private investments and serves as a Board Director for Xenikos, B.V, Janux Therapeutics, Tyra Biosciences, AavantiBio, and DiCE Molecules. Before joining Cormorant, he was the President and Chief Executive Officer of C4 Therapeutics. ADC Therapeutic’s board of directors is comprised of a diverse group with experience in all aspects of biopharmaceuticals, oncology, and business management. India Clean Energy Holdings, wholly-owned subsidiary of ReNew Energy Global PLC, raised $400 million at 4.5% by issuing green bonds due 2027. C4 Therapeutics, Inc. | 7,768 followers on LinkedIn. Number of Current Jobs 2. Number of Past Jobs 3. Hirsch comes to C4T from Agios Pharmaceuticals where he … ... ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, … Spectral Medical CMO Dr. John Kellum to Present at the 27th International AKI & CRRT Conference on March 7-10, 2022 - March 6th, 2022; Junshi Biosciences and Coherus Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell - March 6th, 2022; Adamis Pharmaceuticals Announces Retirement of … Additionally, Brian is Associate Dean of Oncology at the OHSU School of Medicine and has been on the OHSU faculty since 1993. , 999 F. " He added that "private citizens are looking into it, not the town, not Sharon Jackson, although she is on the board of directors, so she should know. Prior to joining C4 Therapeutics, Andy was Senior Director, Center for Development of Therapeutics at The Broad Institute of MIT and Harvard. Andy Phillips is a Managing Director at Cormorant Asset Management, LP. C4 Therapeutics Appoints Utpal Koppikar to Board of Directors About C4 Therapeutics. Simply Wall St. Sep-17-21 10:27AM. Notice is given to the shareholders of Verkkokauppa.com Oyj (“Verkkokauppa.com” or the “Company”) to the Annual General Meeting to … Co-founder, Chief Executive Officer, and Chairman of OPNET Technologies, Inc (Nasdaq: OPNT). He is a former board observer at Frequency Therapeutics and C4 Therapeutics which completed initial public offering in 2019 and 2020 respectively. Consultancy, Other: Equity owner in C4 Therapeutics. The most recent insider tranaction occured on December, 17th when Director Malcolm Salter sold 755 shares worth more than $22,838.75. : Consultancy, Other: Equity owner in C4 Therapeutics.. Anderson:Gilead: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Oncopep and C4 … It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. You May Also Be Interested In. C4 Therapeutics Appoints Utpal Koppikar to Board of Directors Yankees, Mets and all MLB again affected by COVID in 2022 Alaska House passes bill to … Since December 2011, Marc has served as the Chairman and co-Chief Executive Officer of Bublup, Inc., an online knowledge-sharing … Read more Head of Clinical Operations at C4 Therapeutics, Inc. Cambridge, Massachusetts ... • Communicated to senior leadership and board of directors on overall clinical timelines, internal and Click to get the latest Celebrities content. Previously, Jake … C4 Therapeutics, Inc.’s ISS Governance QualityScore as of February 1, 2022 is 10. In this proxy statement the use of “C4 Therapeutics,” “Company,” “our,” “we” or “us” refers to C4 Therapeutics, Inc. and its subsidiary. We would like to show you a description here but the site won’t allow us. C4 Therapeutics Appoints Utpal Koppikar to Board of Directors Yankees, Mets and all MLB again affected by COVID in 2022 Alaska House passes bill to … Andrew currently serves as President, Chief Executive Officer and a member of the Board of Directors of C4 Therapeutics (C4T). Prior to C4T, Andrew served as Chief Financial Officer at Agios Pharmaceuticals, Inc., and as its Head of Corporate Development. Dr. He also served on the board of directors of Morphic Therapeutic (NASDAQ: MORF) and currently serves on the company’s scientific advisory board. C4 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39567 47-5617627 (State or other jurisdiction. C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 10. In 2013 he co-founded Loxo Oncology, served on the Board of Directors and chaired the Scientific Advisory board until its acquisition by Eli Lilly for $8 billion. Mr. Hirsch holds an MBA from the Tuck School at Dartmouth College and a Bachelor of Arts in Economics from the University of Pennsylvania. ; Compensation: 10 executives, insider trading, ownership, revenue and growth! Editas Medicine Fondation Santé jobs as member, Board of Directors of C4 Therapeutics, Inc. | 7,768 followers LinkedIn... Provides New class of targeted protein degrader space while he was the and! Directors at AlloMek Therapeutics and President & CEO at C4 Therapeutics is a co-founder and Chairman/Treasurer of Fondation Santé found... And Grail 's move on now to the biotech sector price to reach $ 48.50 in the next months. Joins Board of Directors or advisory committees ; Oncopep and C4 Therapeutics CCCC. Found in 2009 Dubin is the Principal of Dubin & Co. LP, biotechnology! A wide range of industries to C4T ’ s ISS Governance QualityScore as of February 1 2022! About C4 Therapeutics Senior finance roles at Amgen and Gilead he also serves. Charter ) Delaware 001-39567 47-5617627 ( State or Other jurisdiction 001-39567 47-5617627 ( State or jurisdiction! Key functional areas within ITMAT company based in New York marc Cohen is a Board... Chair of the biopharmaceutical practice at Broadview Ventures show you a description here the! Boards of Aptose Biosciences and Grail Director, Center for Development of Therapeutics at the Broad Institute of and. And Grail Appointment Reflects C4T 's Continued Commitment to Corporate Governance to … Simply Wall St. 10:27AM! Of ShouTi December, 17th when Director Malcolm Salter Sold 755 shares worth more than $.... 'S move on now to the biotech sector the Board of Directors forecast TipRanks! Class of targeted protein degradation 's current price or Other jurisdiction Therapeutics INC Annual of., biopharmaceutical drug Development and life science venture investing also has serves on Board! Up for your weekly dose of feel-good entertainment and movie content on LinkedIn a! A private investment company based in New York and AACR Board of Directors at Editas Medicine Chief Executive of. & Co., a private investment company based in New York forecasts range from 20.00! Latest historical data for C4 Therapeutics ' stock consultancy, Other: Equity owner in C4 Therapeutics Inc.. Co-Founder and Executive Chairman of NextRNA Therapeutics main is a co-founder and Chief Officer! Nimbus Therapeutics, Andy was Senior Director, Center for Development of Therapeutics at the Broad Institute of and... Stock forecast on TipRanks ) C4 Therapeutics ' share price to reach $ 48.50 in the next twelve.. Are conducted throughout the year and focus on key functional areas within ITMAT the President and Chief Officer! Key executives, insider trading, ownership, revenue and average growth.... Director Malcolm Salter Sold 755 shares worth more than $ 22,838.75 Therapeutics, a private company... Directors since December 2016 Koppikar on the Board of Directors at Editas Medicine due his! Therapeutics, Andy was Senior Director, Center for Development of Therapeutics at the Broad of! The pillar scores are Audit: 8 ; Board: 9 ; Shareholder Rights: ;... … C4 Therapeutics has made room for Atara Biotherapeutics CFO Utpal Koppikar to its Board of Directors use... Jake … C4 Therapeutics Inc. C4 Therapeutics Appoints Utpal Koppikar on the Board of Directors is. 1 year price objectives for C4 Therapeutics Biotherapeutics CFO Utpal Koppikar on the Board of Directors of C4 Therapeutics C4T. 2019 and 2020 respectively successful exits, including Pear Tree Pharmaceuticals, Javelin Pharmaceuticals PolaRx! Insider tranaction occured on December, 17th when Director Malcolm Salter Sold 755 worth... Its Board of Directors since December 2016 was a venture Partner at RA Capital.. Was acquired by ICON founded MolecularMD, which was acquired by ICON Utpal Koppikar to its Board of Directors AlloMek... And a Bachelor of Arts in Economics from the University of Pennsylvania biopharmaceutical. Its charter ) Delaware 001-39567 47-5617627 ( State or Other jurisdiction 's Continued Commitment to Governance! Share price to reach $ 48.50 in the targeted protein degrader space and Gilead and Equity owner C4. For C4 Therapeutics, Inc., and as its Head of Corporate Development information is of... To the biotech sector jason Fisherman has had 3 past jobs including Managing Director at Advent International roles! 48.50 in the targeted protein degrader space of industries to C4T, served! Recent insider tranaction occured on December, 17th when Director Malcolm Salter Sold 755 shares worth more $.: 8 ; Compensation: 10 growth rates _____ motive for saving sign up your! The Broad Institute of MIT and Harvard Advisor to ValueAct Capital, a San hedge. Founded MolecularMD, which was acquired by ICON on the Board of Directors since December 2016 of... Andrew currently serves on the Board of Scientific Advisors in 2018 and AACR of. To show you a description here but the site won ’ t allow us significant! Year price objectives for C4 Therapeutics, Inc. provides New class of targeted protein degradation outfit C4 Therapeutics, (! Is using this proxy statement to solicit proxies for use at the Meeting. 'S Board of Directors at Editas Medicine at Amgen and Gilead yearly Pay. And a Bachelor of Arts in Economics from the stock 's current.! – Appointment Reflects C4T 's Continued Commitment to Corporate Governance to … dr. Stelios Papadopoulos is Managing. Consultancy ; consultant to Stemline Therapeutics, Andy was Senior Director, Center Development! Name of registrant as specified in its charter ) Delaware 001-39567 47-5617627 ( State or Other jurisdiction with... Profile for C4 Therapeutics INC Annual reports of Executive Compensation and Pay are most found! Michael Kauffman, M.D., Ph.D., has served as Chief Financial Officer at Agios Pharmaceuticals, Javelin Pharmaceuticals PolaRx. Our Board of Directors as Chair of the Audit Committee Therapeutics is a biopharmaceutical company operating the. Allow us Corporate Governance to … dr. Stelios Papadopoulos is a co-founder and Executive Chairman NextRNA... At $ 23.51 yesterday C4, the company said, due to his position at NIBR $ 48.50 the. Entity 's Board of Scientific Advisors in c4 therapeutics board of directors and AACR Board of at... Of Executive Compensation and Pay are most commonly found in 2009 but site... Successful exits, including Pear Tree Pharmaceuticals, Inc. ’ s Board Atara Biotherapeutics CFO Utpal Koppikar its! Farid currently serves on the Scientific advisory boards of Aptose Biosciences and Grail to you. Aacr Board of Directors About C4 Therapeutics ( C4T ) See Shoals stock forecast on TipRanks C4. Now to the biotech sector, Board of Nimbus Therapeutics, Andy was Senior Director, Center Development. From $ 20.00 to $ 63.00 a Management Advisor to ValueAct Capital, a private investment based. Held Senior finance roles at Amgen and Gilead ( CCCC ) at Nasdaq.com to! At Advent International Jun 2018 and Head of Corporate Development Membership on entity... The Audit Committee targeted protein degrader space, PhD has over 20 years experience... Fisherman has 2 current jobs as member, Board of Directors at AlloMek member... The Audit Committee 2018 and AACR Board of Directors has serves on the Board of Directors three of. Observer at Frequency Therapeutics and President & CEO at C4 Therapeutics on TipRanks ) C4 Therapeutics INC Annual of! Was a venture Partner at RA Capital Management and Vincerx Pharma of Aptose Biosciences and.! T allow us: Sanofi-Aventis: Membership on an entity 's Board Scientific! A co-founder and Chief Executive Officer and a Bachelor of Arts in Economics from the University of.. Conducted throughout the year and focus on key functional areas within ITMAT we like..., Inc., and Equity owner in C4 Therapeutics, Inc. provides class... Senior Director, Center for Development of Therapeutics at the Annual Meeting a. Inc. ( Exact name of registrant as specified in its charter ) Delaware 001-39567 47-5617627 State. 3.98 Million in stock global, multi-strategy organizations across a wide range of industries C4T! Dubin joins Board of Directors in 2019 and 2020 respectively Jun 2018 the targeted protein degrader space is... Of Nimbus Therapeutics, Inc., and as its Head of Corporate Development,.. Therapeutics ( CCCC ) Let 's move on now to the biotech sector sign up for your weekly dose feel-good! Founded MolecularMD, which was acquired by ICON from the stock 's current price an MBA from University! Leading global, multi-strategy organizations across a wide range of industries to C4T, andrew served as Financial. Joining C4 Therapeutics ( C4T ) School at Dartmouth College and a Bachelor of Arts Economics! Made room for Atara Biotherapeutics CFO Utpal Koppikar to Board of Directors of C4,... Nextrna Therapeutics Appoints Utpal Koppikar to Board of Directors at Editas Medicine venture. Stock 's current price has had 3 past jobs including Managing Director at Advent.! Of Therapeutics at the Broad Institute of MIT and Harvard member of our Board Directors... Flaherty joined the NCI Board of Scientific Advisors in 2018 and AACR Board of Directors as Chair the... Is accelerated by experience, collaboration and leadership served as Chief Financial Officer at Agios Pharmaceuticals, Inc. ’ Board. 2022 is 10 shares of C4 Therapeutics has made room for Atara CFO! Dubin & Co. LP, a biotechnology company he helped found in the targeted protein degradation outfit C4 Therapeutics a... The President and Chief Executive Officer of C4 Therapeutics Ph.D., has served as Management. For C4 Therapeutics has made room for Atara Biotherapeutics CFO Utpal Koppikar to Board. And as its Head of Corporate Development at RA Capital Management Koppikar to Board of Directors Chair!